Vergoeding 2019-2023 voor ATC-subgroep A10B : Bloedglucoseverlagende middelen excl. insulines
- Raming voor de totale Zvw-populatie
| 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|
| A10BA Biguaniden | 9.134.200 | 10.353.400 | 12.048.000 | 12.339.900 | 14.317.900 |
| A10BB Sulfonylureumderivaten | 8.661.500 | 8.875.300 | 10.602.100 | 10.961.000 | 14.623.000 |
| A10BD Combinaties van bloedglucoseverlagende middelen | 3.622.200 | 3.630.300 | 3.518.700 | 3.544.800 | 2.999.600 |
| A10BF Alfa-glucosidaseremmers | 125.090 | 109.760 | 95.128 | 81.052 | 36.740 |
| A10BG Thiazolidinedionen | 81.449 | 61.009 | 83.232 | 298.580 | 395.300 |
| A10BH Dipeptidylpeptidase-4-remmers | 14.413.100 | 15.614.900 | 15.208.700 | 15.482.500 | 12.244.400 |
| A10BJ Glucagonachtig peptide-1-agonisten (glp-1-agonisten) | 26.529.600 | 40.054.500 | 50.379.200 | 80.495.200 | 117.216.000 |
| A10BK Natriumglucose-cotransporter-2-remmers (sglt-2-remmers) | 6.186.500 | 7.384.800 | 10.195.300 | 34.366.200 | 62.486.700 |
| A10BX Overige bloedglucoseverlagende middelen excl. insulines | 50.757 | 54.144 | 51.168 | 49.716 | 46.323 |
| Totaal | 68.804.396 | 86.138.113 | 102.181.528 | 157.618.948 | 224.365.963 |